董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Smital Shah | 女 | Director | 46 | 8.40万美元 | 未持股 | 2023-04-20 |
| Jerel Davis | 男 | Director | 46 | 8.05万美元 | 未持股 | 2023-04-20 |
| Carlo Rizzuto | 男 | Director | 52 | 7.90万美元 | 未持股 | 2023-04-20 |
| Jo Viney | 女 | Director | 57 | 7.90万美元 | 未持股 | 2023-04-20 |
| Abraham Bassan | 男 | Director | 38 | 7.90万美元 | 未持股 | 2023-04-20 |
| Kristen M. Hege | 女 | Director | 59 | 7.90万美元 | 未持股 | 2023-04-20 |
| Matthew Porteus | 男 | Director | 58 | 14.40万美元 | 未持股 | 2023-04-20 |
| Josh Lehrer | 男 | President, Chief Executive Officer and Director | 49 | 549.05万美元 | 未持股 | 2023-04-20 |
| Joseph Jimenez | 男 | Director | 63 | 8.05万美元 | 未持股 | 2023-04-20 |
| Perry Karsen | 男 | Director and Board Chair | 68 | 11.20万美元 | 未持股 | 2023-04-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Josh Lehrer | 男 | President, Chief Executive Officer and Director | 49 | 549.05万美元 | 未持股 | 2023-04-20 |
| Alethia Young | 女 | Chief Financial Officer | 44 | 183.55万美元 | 未持股 | 2023-04-20 |
董事简历
中英对照 | 中文 | 英文- Smital Shah
-
Smital Shah自2019年3月以来一直担任我们的董事会成员。自2014年10月以来，Shah女士一直在ProQR Therapeutics NV（一家罕见疾病公司）担任越来越重要的职务，包括担任首席财务官，最近担任首席业务和财务官。此前，沙阿女士管理着吉利德科学公司数十亿美元的债务、现金和投资组合。任职Gilead公司之前，她曾担任Leerink Partners公司和JP Morgan公司的投资银行家，专注于生物技术领域的资本筹集和战略交易。此前，Shah女士在强生公司公司担任过各种研究与开发职务。她持有孟买大学（the University of Mumbai）的化学工程学士学位、弗吉尼亚理工大学（Virginia Tech）的化学工程硕士学位和加州大学伯克利分校哈斯商学院（the University of Berkeley Haas School of Business）的工商管理硕士学位。
Smital Shah,has served as a member of Graphite Bio, Inc. board of directors since April 2021. Ms. Shah currently serves on the board of directors of Pliant Therapeutics, Inc. (NASDAQ: PLRX) since March 2019. From December 2018 to December 2022, Ms. Shah was the Chief Business and Financial Officer at ProQR Therapeutics NV (NASDAQ: PRQR) and prior to that, she was the company's Chief Financial Officer from October 2014 to December 2018. From August 2012 to September 2014, Ms. Shah was in Corporate Treasury at Gilead Sciences, Inc. (NASDAQ: GILD). Prior to Gilead Sciences, Inc., she was an investment banker at Leerink Partners LLC and JP Morgan Chase and Co., where she focused on capital raising and strategic transactions in the biotechnology space. Ms. Shah also held various research and development roles at Johnson & Johnson Company. Ms. Shah holds a B.S. in Chemical Engineering from the University of Mumbai, a M.S. in Chemical Engineering from Virginia Tech and an M.B.A. from the University of California, Berkeley Haas School of Business. - Smital Shah自2019年3月以来一直担任我们的董事会成员。自2014年10月以来，Shah女士一直在ProQR Therapeutics NV（一家罕见疾病公司）担任越来越重要的职务，包括担任首席财务官，最近担任首席业务和财务官。此前，沙阿女士管理着吉利德科学公司数十亿美元的债务、现金和投资组合。任职Gilead公司之前，她曾担任Leerink Partners公司和JP Morgan公司的投资银行家，专注于生物技术领域的资本筹集和战略交易。此前，Shah女士在强生公司公司担任过各种研究与开发职务。她持有孟买大学（the University of Mumbai）的化学工程学士学位、弗吉尼亚理工大学（Virginia Tech）的化学工程硕士学位和加州大学伯克利分校哈斯商学院（the University of Berkeley Haas School of Business）的工商管理硕士学位。
- Smital Shah,has served as a member of Graphite Bio, Inc. board of directors since April 2021. Ms. Shah currently serves on the board of directors of Pliant Therapeutics, Inc. (NASDAQ: PLRX) since March 2019. From December 2018 to December 2022, Ms. Shah was the Chief Business and Financial Officer at ProQR Therapeutics NV (NASDAQ: PRQR) and prior to that, she was the company's Chief Financial Officer from October 2014 to December 2018. From August 2012 to September 2014, Ms. Shah was in Corporate Treasury at Gilead Sciences, Inc. (NASDAQ: GILD). Prior to Gilead Sciences, Inc., she was an investment banker at Leerink Partners LLC and JP Morgan Chase and Co., where she focused on capital raising and strategic transactions in the biotechnology space. Ms. Shah also held various research and development roles at Johnson & Johnson Company. Ms. Shah holds a B.S. in Chemical Engineering from the University of Mumbai, a M.S. in Chemical Engineering from Virginia Tech and an M.B.A. from the University of California, Berkeley Haas School of Business.
- Jerel Davis
-
Jerel Davis自2016年9月成立以来一直担任我们的董事会主席。自2011年6月起，Davis博士一直在Versant Venture Management，LLC（一家梦百合投资公司）任职，自2015年起担任董事总经理。他在Versant的公司创建战略中发挥了关键作用，并在许多公共和私人生物技术公司的董事会任职，包括Bluerock Therapeutics，Turnstone Biologics，Chinook Therapeutics，Inception5和Northern Biologics。在加入Versant公司之前，戴维斯博士是麦肯锡公司在包括美国、加拿大、欧洲和中国在内的多个梦百合市场的副总裁。他获得Pepperdine University的数学和生物学学士学位，以及Stanford University的人口遗传学博士学位。
Jerel Davis,has served on Graphite Bio, Inc. board of directors since the Company's inception in October 2019. Dr. Davis is currently a Managing Director of Versant Venture Management, LLC, a healthcare investment firm which he joined in 2012 and has held his current role since 2015. Dr. Davis currently serves on the boards of public companies, Chinook Therapeutics, Inc. (NASDAQ GS: KDNY) since December 2018 and Repare Therapeutics, Inc. (NASDAQ: RPTX) since September 2016. Dr. Davis also serves on the boards of a number of private companies including Nested Therapeutics, Inc., RayzeBio, Inc., Tentarix Biotherapeutics, Inc., Ventus Therapeutics Inc., and Turnstone Biologics Corp., among others. Prior to joining Versant Venture Management, LLC, Dr. Davis worked at McKinsey & Company, Inc., where he serviced various healthcare markets including the United States, Europe and China. Dr. Davis received a B.S. in Mathematics and Biology from Pepperdine University and a Ph.D. in Population Genetics from Stanford University. - Jerel Davis自2016年9月成立以来一直担任我们的董事会主席。自2011年6月起，Davis博士一直在Versant Venture Management，LLC（一家梦百合投资公司）任职，自2015年起担任董事总经理。他在Versant的公司创建战略中发挥了关键作用，并在许多公共和私人生物技术公司的董事会任职，包括Bluerock Therapeutics，Turnstone Biologics，Chinook Therapeutics，Inception5和Northern Biologics。在加入Versant公司之前，戴维斯博士是麦肯锡公司在包括美国、加拿大、欧洲和中国在内的多个梦百合市场的副总裁。他获得Pepperdine University的数学和生物学学士学位，以及Stanford University的人口遗传学博士学位。
- Jerel Davis,has served on Graphite Bio, Inc. board of directors since the Company's inception in October 2019. Dr. Davis is currently a Managing Director of Versant Venture Management, LLC, a healthcare investment firm which he joined in 2012 and has held his current role since 2015. Dr. Davis currently serves on the boards of public companies, Chinook Therapeutics, Inc. (NASDAQ GS: KDNY) since December 2018 and Repare Therapeutics, Inc. (NASDAQ: RPTX) since September 2016. Dr. Davis also serves on the boards of a number of private companies including Nested Therapeutics, Inc., RayzeBio, Inc., Tentarix Biotherapeutics, Inc., Ventus Therapeutics Inc., and Turnstone Biologics Corp., among others. Prior to joining Versant Venture Management, LLC, Dr. Davis worked at McKinsey & Company, Inc., where he serviced various healthcare markets including the United States, Europe and China. Dr. Davis received a B.S. in Mathematics and Biology from Pepperdine University and a Ph.D. in Population Genetics from Stanford University.
- Carlo Rizzuto
-
Carlo Rizzuto自2018年1月以来一直担任我们的董事会成员。Rizzuto博士于2012年11月加入Versant Ventures，担任运营负责人，于2015年成为风险合伙人，并于2017年成为合伙人。他此前曾任职Novartis Pharmaceuticals公司，在那里他曾担任全球项目团队董事（从2010年7月到2012年10月）。Rizzuto博士在哈佛大学（Harvard University）获得病毒学博士学位，在弗吉尼亚大学（University of Virginia）获得生物学学士学位。
Carlo Rizzuto,has served as a member of Graphite Bio, Inc. board of directors since March 2020. Dr. Rizzuto is currently a Managing Director at Versant Venture Management, LLC, a healthcare investment firm. He has been with the firm since November 2012 where he has served in a variety of roles including operating principal, venture partner and partner. Prior to that, Dr. Rizzuto worked at Novartis AG, where he was a Global Program Team Director from 2010 to 2012. Dr. Rizzuto currently serves on the board of directors of Century Therapeutics, Inc. (NASDAQ: IPSC) since March 2018 and previously served on the board of directors of Pandion Therapeutics, Inc., from January 2018 until its acquisition by Merck (NYSE: MRK) in March 2021. Dr. Rizzuto received a B.A. in Biology from the University of Virginia and a Ph.D. in Virology from Harvard University. - Carlo Rizzuto自2018年1月以来一直担任我们的董事会成员。Rizzuto博士于2012年11月加入Versant Ventures，担任运营负责人，于2015年成为风险合伙人，并于2017年成为合伙人。他此前曾任职Novartis Pharmaceuticals公司，在那里他曾担任全球项目团队董事（从2010年7月到2012年10月）。Rizzuto博士在哈佛大学（Harvard University）获得病毒学博士学位，在弗吉尼亚大学（University of Virginia）获得生物学学士学位。
- Carlo Rizzuto,has served as a member of Graphite Bio, Inc. board of directors since March 2020. Dr. Rizzuto is currently a Managing Director at Versant Venture Management, LLC, a healthcare investment firm. He has been with the firm since November 2012 where he has served in a variety of roles including operating principal, venture partner and partner. Prior to that, Dr. Rizzuto worked at Novartis AG, where he was a Global Program Team Director from 2010 to 2012. Dr. Rizzuto currently serves on the board of directors of Century Therapeutics, Inc. (NASDAQ: IPSC) since March 2018 and previously served on the board of directors of Pandion Therapeutics, Inc., from January 2018 until its acquisition by Merck (NYSE: MRK) in March 2021. Dr. Rizzuto received a B.A. in Biology from the University of Virginia and a Ph.D. in Virology from Harvard University.
- Jo Viney
-
Jo Viney自2019年8月以来一直担任我们的董事会成员。Viney博士是联合创始人，自2017年4月起担任PandionTherapeutics，Inc.首席科学官，自2019年7月起担任总裁。2015年11月至2016年11月，Viney博士在BiogenInc.担任高级副总裁，药物发现，2011年7月至2015年10月，他担任免疫学研究Vice President。Viney从2003年9月到2011年4月担任Amgen，Inc.炎症研究执行主管，此前从2002年7月到2003年8月担任炎症研究主管。Viney博士自2020年7月起担任HarpoonTherapeutics，Inc.董事会成员，此前曾担任和目前担任多家私营公司董事会成员。Viney博士拥有the University of London，St.Bartholomew’s Hospital Medical School免疫学博士学位和理学学士学位。来自东伦敦大学。
Jo Viney,has served as a member of Graphite Bio, Inc. board of directors since March 2021. Since October 2021, Dr. Viney has been a Co-Founder, President and Chief Executive Officer of Seismic Therapeutic, Inc., a biotechnology company. From July 2019 to October 2021, Dr. Viney was the Co-Founder and President of Pandion Therapeutics Inc. (NASDAQ: PAND), subsequently acquired by Merck & Co Inc. (NYSE: MRK), after serving as its Chief Scientific Officer since April 2017. From November 2015 to November 2016, Dr. Viney served as Senior Vice President, Drug Discovery at Biogen Inc. (NASDAQ: BIIB), after serving as Vice President, Immunology Research from July 2011 to October 2015. From September 2003 to April 2011, Dr. Viney served as Executive Director of Inflammation Research at Amgen, Inc. (NASDAQ: AMGN), after serving as Director of Inflammation Research from July 2002 to August 2003. Dr. Viney currently serves on the boards of public biotechnology companies, Harpoon Therapeutics, Inc. (NASDAQ: HARP) and Finch Therapeutics Group, Inc. (NASDAQ: FNCH). Dr. Viney holds a BSc in Biophysical Science from the University of East London and a Ph.D. in Immunology from the University of London, St. Bartholomew's Hospital Medical School. - Jo Viney自2019年8月以来一直担任我们的董事会成员。Viney博士是联合创始人，自2017年4月起担任PandionTherapeutics，Inc.首席科学官，自2019年7月起担任总裁。2015年11月至2016年11月，Viney博士在BiogenInc.担任高级副总裁，药物发现，2011年7月至2015年10月，他担任免疫学研究Vice President。Viney从2003年9月到2011年4月担任Amgen，Inc.炎症研究执行主管，此前从2002年7月到2003年8月担任炎症研究主管。Viney博士自2020年7月起担任HarpoonTherapeutics，Inc.董事会成员，此前曾担任和目前担任多家私营公司董事会成员。Viney博士拥有the University of London，St.Bartholomew’s Hospital Medical School免疫学博士学位和理学学士学位。来自东伦敦大学。
- Jo Viney,has served as a member of Graphite Bio, Inc. board of directors since March 2021. Since October 2021, Dr. Viney has been a Co-Founder, President and Chief Executive Officer of Seismic Therapeutic, Inc., a biotechnology company. From July 2019 to October 2021, Dr. Viney was the Co-Founder and President of Pandion Therapeutics Inc. (NASDAQ: PAND), subsequently acquired by Merck & Co Inc. (NYSE: MRK), after serving as its Chief Scientific Officer since April 2017. From November 2015 to November 2016, Dr. Viney served as Senior Vice President, Drug Discovery at Biogen Inc. (NASDAQ: BIIB), after serving as Vice President, Immunology Research from July 2011 to October 2015. From September 2003 to April 2011, Dr. Viney served as Executive Director of Inflammation Research at Amgen, Inc. (NASDAQ: AMGN), after serving as Director of Inflammation Research from July 2002 to August 2003. Dr. Viney currently serves on the boards of public biotechnology companies, Harpoon Therapeutics, Inc. (NASDAQ: HARP) and Finch Therapeutics Group, Inc. (NASDAQ: FNCH). Dr. Viney holds a BSc in Biophysical Science from the University of East London and a Ph.D. in Immunology from the University of London, St. Bartholomew's Hospital Medical School.
- Abraham Bassan
-
Abraham Bassan自2020年6月以来一直担任我们的董事会成员。自2017年7月以来，Bassan先生一直担任Samsara Biocapital的副总裁。在加入Samsara Biocapital之前，Bassan先生于2015年10月至2017年7月担任RevolutionMedicines，Inc.的项目生物学总监，并于2014年12月至2015年9月担任其项目管理总监。Bassan先生于2012年9月至2014年9月担任Aurora Medical，Inc.的创始人兼首席执行官。从2010年5月到2012年8月，Bassan先生还担任bluebirdbio，Inc.的项目开发副总监。Bassan先生拥有普林斯顿大学分子生物学学士学位和斯坦福大学发展生物学硕士学位。
Abraham Bassan,has served as a member of Cargo Therapeutics, Inc. board of directors since February 2021. Since April 2021, Mr. Bassan has served as a Principal at Samsara BioCapital, a privately held life science investment firm. From July 2017 to April 2021, Mr. Bassan served as a Vice President at Samsara BioCapital. From December 2014 to July 2017, Mr. Bassan served as Director of Program Biology at Revolution Medicines, a then privately held oncology company. Prior to that, from 2010 to 2012, Mr. Bassan served as Associate Director of Program Management at bluebird bio, Inc., a publicly traded biotechnology company. Mr. Bassan currently serves as a member of the board of directors at Graphite Bio, Inc. Mr. Bassan received an A.B. in Molecular Biology from Princeton University and an M.S. in Developmental Biology from Stanford University. - Abraham Bassan自2020年6月以来一直担任我们的董事会成员。自2017年7月以来，Bassan先生一直担任Samsara Biocapital的副总裁。在加入Samsara Biocapital之前，Bassan先生于2015年10月至2017年7月担任RevolutionMedicines，Inc.的项目生物学总监，并于2014年12月至2015年9月担任其项目管理总监。Bassan先生于2012年9月至2014年9月担任Aurora Medical，Inc.的创始人兼首席执行官。从2010年5月到2012年8月，Bassan先生还担任bluebirdbio，Inc.的项目开发副总监。Bassan先生拥有普林斯顿大学分子生物学学士学位和斯坦福大学发展生物学硕士学位。
- Abraham Bassan,has served as a member of Cargo Therapeutics, Inc. board of directors since February 2021. Since April 2021, Mr. Bassan has served as a Principal at Samsara BioCapital, a privately held life science investment firm. From July 2017 to April 2021, Mr. Bassan served as a Vice President at Samsara BioCapital. From December 2014 to July 2017, Mr. Bassan served as Director of Program Biology at Revolution Medicines, a then privately held oncology company. Prior to that, from 2010 to 2012, Mr. Bassan served as Associate Director of Program Management at bluebird bio, Inc., a publicly traded biotechnology company. Mr. Bassan currently serves as a member of the board of directors at Graphite Bio, Inc. Mr. Bassan received an A.B. in Molecular Biology from Princeton University and an M.S. in Developmental Biology from Stanford University.
- Kristen M. Hege
-
Kristen M.Hege自2021年4月以来一直担任我们的董事会成员。Hege博士于2010年9月加入新基医药公司，担任转化开发副总裁，现任Bristol Myers Squibb Company血液学/肿瘤学和细胞疗法早期临床开发高级副总裁，该公司于2019年11月收购Celgene。Hege博士自1996年7月以来还一直在加利福尼亚大学旧金山医学中心担任活跃的教师职位，最近担任血液学/肿瘤学医学临床教授，自2008年7月以来一直担任志愿者。在加入Celgene之前，Hege博士于2009年11月至2010年9月担任Cellerant Therapeutics的首席医疗官，于2010年1月至2010年9月担任Aragon Pharmaceuticals的代理首席医疗官，并于2009年3月担任Theraclone Sciences的代理首席医疗官。2010年9月。从1996年7月到2008年10月，Hege博士还担任Cell Genesys临床研究与开发的副总裁。Hege博士曾于2016年1月至2019年1月担任癌症免疫疗法协会的大型志愿者主任，并于2014年1月至2016年1月担任BayBio/加利福尼亚生命科学协会的主任。Hege博士自2016年8月起担任MersanaTherapeutics，Inc.董事会成员。她还曾于2018年10月至2019年11月担任Arcus Biosciences的董事会成员，并于2014年4月至2015年3月担任Flexus Biosciences的董事会观察员。Hege博士以优异的成绩获得了达特茅斯学院的生物化学学士学位，加利福尼亚大学旧金山分校的医学博士学位以及加利福尼亚大学旧金山分校的血液学和医学肿瘤学董事会认证。
Kristen M. Hege,has served as a member of Graphite Bio, Inc. board of directors since April 2021. Dr. Hege joined Celgene Corporation in 2010 as Vice President, Translational Development and is currently Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb Company (NYSE: BMY) (following its acquisition of Celgene Corporation in 2019). Prior to Celgene Corporation, she served as Chief Medical Officer at Cellerant Therapeutics, Inc. and Acting Chief Medical Officer at Aragon Pharmaceuticals, Inc. and Theraclone Sciences, Inc.. Dr. Hege was also Vice President, Clinical Research and Development at Cell Genesys. She currently serves as a member of the board of directors at Mersana Therapeutics, Inc. (NASDAQ: MRSN) since 2016 and has previously served as a member of the board of directors at Arcus Biosciences, Inc. (NYSE: RCUS) from 2018 to 2019 and as a Board Observer for Flexus Biosciences from 2014 to 2015. She also previously served as a Volunteer-at-Large Director for the Society for Immunotherapy of Cancer from 2016 to 2019 and the BayBio/California Life Sciences Association from 2014 to 2016. Dr. Hege is currently a volunteer Clinical Professor of Medicine, Hematology/Oncology at the University of California, San Francisco Medical Center, where she was previously an active faculty member since 1996. Dr. Hege received a B.A. in Biochemistry from Dartmouth College summa cum laude, an M.D. from University of California, San Francisco, Internal Medicine training at Harvard's Brigham & Women's Hospital, and Board certification in Hematology and Medical Oncology from the University of California, San Francisco. - Kristen M.Hege自2021年4月以来一直担任我们的董事会成员。Hege博士于2010年9月加入新基医药公司，担任转化开发副总裁，现任Bristol Myers Squibb Company血液学/肿瘤学和细胞疗法早期临床开发高级副总裁，该公司于2019年11月收购Celgene。Hege博士自1996年7月以来还一直在加利福尼亚大学旧金山医学中心担任活跃的教师职位，最近担任血液学/肿瘤学医学临床教授，自2008年7月以来一直担任志愿者。在加入Celgene之前，Hege博士于2009年11月至2010年9月担任Cellerant Therapeutics的首席医疗官，于2010年1月至2010年9月担任Aragon Pharmaceuticals的代理首席医疗官，并于2009年3月担任Theraclone Sciences的代理首席医疗官。2010年9月。从1996年7月到2008年10月，Hege博士还担任Cell Genesys临床研究与开发的副总裁。Hege博士曾于2016年1月至2019年1月担任癌症免疫疗法协会的大型志愿者主任，并于2014年1月至2016年1月担任BayBio/加利福尼亚生命科学协会的主任。Hege博士自2016年8月起担任MersanaTherapeutics，Inc.董事会成员。她还曾于2018年10月至2019年11月担任Arcus Biosciences的董事会成员，并于2014年4月至2015年3月担任Flexus Biosciences的董事会观察员。Hege博士以优异的成绩获得了达特茅斯学院的生物化学学士学位，加利福尼亚大学旧金山分校的医学博士学位以及加利福尼亚大学旧金山分校的血液学和医学肿瘤学董事会认证。
- Kristen M. Hege,has served as a member of Graphite Bio, Inc. board of directors since April 2021. Dr. Hege joined Celgene Corporation in 2010 as Vice President, Translational Development and is currently Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb Company (NYSE: BMY) (following its acquisition of Celgene Corporation in 2019). Prior to Celgene Corporation, she served as Chief Medical Officer at Cellerant Therapeutics, Inc. and Acting Chief Medical Officer at Aragon Pharmaceuticals, Inc. and Theraclone Sciences, Inc.. Dr. Hege was also Vice President, Clinical Research and Development at Cell Genesys. She currently serves as a member of the board of directors at Mersana Therapeutics, Inc. (NASDAQ: MRSN) since 2016 and has previously served as a member of the board of directors at Arcus Biosciences, Inc. (NYSE: RCUS) from 2018 to 2019 and as a Board Observer for Flexus Biosciences from 2014 to 2015. She also previously served as a Volunteer-at-Large Director for the Society for Immunotherapy of Cancer from 2016 to 2019 and the BayBio/California Life Sciences Association from 2014 to 2016. Dr. Hege is currently a volunteer Clinical Professor of Medicine, Hematology/Oncology at the University of California, San Francisco Medical Center, where she was previously an active faculty member since 1996. Dr. Hege received a B.A. in Biochemistry from Dartmouth College summa cum laude, an M.D. from University of California, San Francisco, Internal Medicine training at Harvard's Brigham & Women's Hospital, and Board certification in Hematology and Medical Oncology from the University of California, San Francisco.
- Matthew Porteus
-
Matthew Porteus自2020年3月以来一直担任我们的董事会成员。Porteus博士是斯坦福医学院血液学/肿瘤学和人类基因疗法部门儿科副教授，自2010年10月以来，他一直担任各种领导职务。在加入斯坦福大学之前，Porteus博士于2003年2月至2010年8月担任德克萨斯大学西南医学中心助理教授。他的研究重点是开发基于基因和其他疾病的同源重组疗法。Porteus博士还在Lucille Packard Children&8217；S医院拥有临床业务，他是儿科骨髓移植服务的主治医生。Porteus博士以优异的成绩毕业于哈佛大学历史与科学工商管理硕士学位，并在斯坦福大学完成了硕士和博士学位。Porteus博士在波士顿儿童医院（Boston Children&8217；S Hospital）完成了儿科住院医师培训，并在波士顿儿童医院（Boston Children&8217；S Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了儿科血液学/肿瘤学的研究金培训。Porteus博士的博士后工作在麻省理工学院和加利福尼亚理工学院进行培训。在此期间，他开始研究基因编辑，并首次证明工程核酸酶可以通过同源重组来精确修饰人类细胞。
Matthew Porteus,has served on Graphite Bio, Inc. board of directors since March 2020. Dr. Porteus is an Associate Professor of Pediatrics of the Department of Pediatrics, Divisions of Hematology/Oncology and Human Gene Therapy, at Stanford School of Medicine, where he has served in various leadership roles since October 2010. Prior to joining Stanford, Dr. Porteus served as an Assistant Professor at the University of Texas Southwestern Medical Center from February 2003 to August 2010. His research focuses on developing homologous recombination-based therapies for genetic and other diseases. Dr. Porteus also maintains a clinical practice at the Lucille Packard Children's Hospital, where he is an Attending Physician for the Pediatric Bone Marrow Transplant Service. Dr. Porteus completed his residency training in Pediatrics at Boston Children's Hospital and fellowship training in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana Farber Cancer Institute. For his post-doctoral work, Dr. Porteus trained at the Massachusetts Institute of Technology and the California Institute of Technology. During this time, he began studying gene editing and was the first to show that engineered nucleases could be Graphite Bio, Inc. ed to precisely modify human cells by homologous recombination. Dr. Porteus graduated Magna Cum Laude with an A.B. in History and Science from Harvard University and completed his M.D. and Ph.D. degrees at Stanford University. - Matthew Porteus自2020年3月以来一直担任我们的董事会成员。Porteus博士是斯坦福医学院血液学/肿瘤学和人类基因疗法部门儿科副教授，自2010年10月以来，他一直担任各种领导职务。在加入斯坦福大学之前，Porteus博士于2003年2月至2010年8月担任德克萨斯大学西南医学中心助理教授。他的研究重点是开发基于基因和其他疾病的同源重组疗法。Porteus博士还在Lucille Packard Children&8217；S医院拥有临床业务，他是儿科骨髓移植服务的主治医生。Porteus博士以优异的成绩毕业于哈佛大学历史与科学工商管理硕士学位，并在斯坦福大学完成了硕士和博士学位。Porteus博士在波士顿儿童医院（Boston Children&8217；S Hospital）完成了儿科住院医师培训，并在波士顿儿童医院（Boston Children&8217；S Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了儿科血液学/肿瘤学的研究金培训。Porteus博士的博士后工作在麻省理工学院和加利福尼亚理工学院进行培训。在此期间，他开始研究基因编辑，并首次证明工程核酸酶可以通过同源重组来精确修饰人类细胞。
- Matthew Porteus,has served on Graphite Bio, Inc. board of directors since March 2020. Dr. Porteus is an Associate Professor of Pediatrics of the Department of Pediatrics, Divisions of Hematology/Oncology and Human Gene Therapy, at Stanford School of Medicine, where he has served in various leadership roles since October 2010. Prior to joining Stanford, Dr. Porteus served as an Assistant Professor at the University of Texas Southwestern Medical Center from February 2003 to August 2010. His research focuses on developing homologous recombination-based therapies for genetic and other diseases. Dr. Porteus also maintains a clinical practice at the Lucille Packard Children's Hospital, where he is an Attending Physician for the Pediatric Bone Marrow Transplant Service. Dr. Porteus completed his residency training in Pediatrics at Boston Children's Hospital and fellowship training in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana Farber Cancer Institute. For his post-doctoral work, Dr. Porteus trained at the Massachusetts Institute of Technology and the California Institute of Technology. During this time, he began studying gene editing and was the first to show that engineered nucleases could be Graphite Bio, Inc. ed to precisely modify human cells by homologous recombination. Dr. Porteus graduated Magna Cum Laude with an A.B. in History and Science from Harvard University and completed his M.D. and Ph.D. degrees at Stanford University.
- Josh Lehrer
-
Josh Lehrer自2020年4月起担任我们的总裁兼首席执行官兼董事会成员。从2013年10月到2020年4月，Lehrer博士在全球血液疗法公司担任过各种领导职务，包括首席医疗官。从2009年9月到2013年10月，Lehrer博士在Genentech担任临床开发和业务开发的领导职务。莱勒博士还曾在斯坦福大学医学中心和帕洛阿尔托医疗系统担任主治医师。他拥有哈佛大学生化科学学士学位和剑桥大学生物科学哲学硕士学位。Lehrer博士在加利福尼亚大学旧金山分校UCSF医学院获得了医学博士学位，并完成了在UCSF的内科住院医师资格。Lehrer博士曾在斯坦福大学担任心血管医学的临床和博士后研究员，并参加了斯坦福商学院的创业研究所。
Josh Lehrer,has served as Graphite Bio, Inc. President, Chief Executive Officer and on Graphite Bio, Inc. board of directors since April 2020. From October 2013 to April 2020, Dr. Lehrer held various leadership roles at Global Blood Therapeutics, Inc. (NASDAQ: GBT) (acquired by Pfizer, Inc. in October 2022), including Chief Medical Officer where he oversaw the development and approval of Oxbryta (voxelotor) for the treatment of sickle cell disease. From September 2009 to October 2013, Dr. Lehrer served in leadership roles at Genentech, Inc. in clinical development and business development. Dr. Lehrer has also held attending physician roles at Stanford University Medical Center and the Palo Alto Veteran's Affairs Health System. He holds an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. Dr. Lehrer earned his Doctor of Medicine at the University of California, San Francisco (UCSF), School of Medicine and completed his residency at UCSF in Internal Medicine. Dr. Lehrer served as a Clinical and Postdoctoral Fellow in cardiovascular medicine at Stanford University and attended the Institute for Entrepreneurship at the Stanford Graduate School of Business. - Josh Lehrer自2020年4月起担任我们的总裁兼首席执行官兼董事会成员。从2013年10月到2020年4月，Lehrer博士在全球血液疗法公司担任过各种领导职务，包括首席医疗官。从2009年9月到2013年10月，Lehrer博士在Genentech担任临床开发和业务开发的领导职务。莱勒博士还曾在斯坦福大学医学中心和帕洛阿尔托医疗系统担任主治医师。他拥有哈佛大学生化科学学士学位和剑桥大学生物科学哲学硕士学位。Lehrer博士在加利福尼亚大学旧金山分校UCSF医学院获得了医学博士学位，并完成了在UCSF的内科住院医师资格。Lehrer博士曾在斯坦福大学担任心血管医学的临床和博士后研究员，并参加了斯坦福商学院的创业研究所。
- Josh Lehrer,has served as Graphite Bio, Inc. President, Chief Executive Officer and on Graphite Bio, Inc. board of directors since April 2020. From October 2013 to April 2020, Dr. Lehrer held various leadership roles at Global Blood Therapeutics, Inc. (NASDAQ: GBT) (acquired by Pfizer, Inc. in October 2022), including Chief Medical Officer where he oversaw the development and approval of Oxbryta (voxelotor) for the treatment of sickle cell disease. From September 2009 to October 2013, Dr. Lehrer served in leadership roles at Genentech, Inc. in clinical development and business development. Dr. Lehrer has also held attending physician roles at Stanford University Medical Center and the Palo Alto Veteran's Affairs Health System. He holds an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. Dr. Lehrer earned his Doctor of Medicine at the University of California, San Francisco (UCSF), School of Medicine and completed his residency at UCSF in Internal Medicine. Dr. Lehrer served as a Clinical and Postdoctoral Fellow in cardiovascular medicine at Stanford University and attended the Institute for Entrepreneurship at the Stanford Graduate School of Business.
- Joseph Jimenez
-
Joseph Jimenez，自2010年2月，他担任Novartis AG公司的首席执行官。他于2007年4月加盟Novartis AG公司并担任消费者健康部门的负责人，于2007年10月担任制药部门的负责人。在加盟Novartis AG公司前，即自2006年至2007年，他曾在The Blackstone集团这家私募股权投资机构担任顾问。他于1998年加盟H.J. Heinz公司（Heinz公司）并担任总裁和首席执行官，负责Heinz公司的北美洲业务，并于2002年担任总裁和首席执行官，负责Heinz公司的欧洲业务，直至2006年卸任。他在The Clorox公司（Clorox公司）开始其职业生涯，负责品牌管理事务，之后曾在ConAgra Grocery Products公司（ConAgra公司）的两个运营部门担任总裁。
Joseph Jimenez,is Co-Founder and Managing Director of Aditum Bio (biotech venture fund). He is the former Chief Executive Officer of Novartis AG (global healthcare), a position he held from 2010 to 2018. Prior to this role, he held several senior positions at Novartis from 2007 to 2010, including Division Head, Novartis Pharmaceuticals, and leadership of the company's Consumer Health Division. Mr. Jimenez was an Advisor to the Blackstone Group L.P. from 2006 to 2007. He also held various leadership roles at H. J. Heinz Company (packaged food) in Europe and North America from 1999 to 2006, including Executive Vice President, President, and CEO of Heinz Europe from 2002 to 2006 and President and CEO of H.J. Heinz Company North America from 1999 to 2002. Mr. Jimenez also held several leadership positions at ConAgra Foods (packaged food) from 1993 to 1998. - Joseph Jimenez，自2010年2月，他担任Novartis AG公司的首席执行官。他于2007年4月加盟Novartis AG公司并担任消费者健康部门的负责人，于2007年10月担任制药部门的负责人。在加盟Novartis AG公司前，即自2006年至2007年，他曾在The Blackstone集团这家私募股权投资机构担任顾问。他于1998年加盟H.J. Heinz公司（Heinz公司）并担任总裁和首席执行官，负责Heinz公司的北美洲业务，并于2002年担任总裁和首席执行官，负责Heinz公司的欧洲业务，直至2006年卸任。他在The Clorox公司（Clorox公司）开始其职业生涯，负责品牌管理事务，之后曾在ConAgra Grocery Products公司（ConAgra公司）的两个运营部门担任总裁。
- Joseph Jimenez,is Co-Founder and Managing Director of Aditum Bio (biotech venture fund). He is the former Chief Executive Officer of Novartis AG (global healthcare), a position he held from 2010 to 2018. Prior to this role, he held several senior positions at Novartis from 2007 to 2010, including Division Head, Novartis Pharmaceuticals, and leadership of the company's Consumer Health Division. Mr. Jimenez was an Advisor to the Blackstone Group L.P. from 2006 to 2007. He also held various leadership roles at H. J. Heinz Company (packaged food) in Europe and North America from 1999 to 2006, including Executive Vice President, President, and CEO of Heinz Europe from 2002 to 2006 and President and CEO of H.J. Heinz Company North America from 1999 to 2002. Mr. Jimenez also held several leadership positions at ConAgra Foods (packaged food) from 1993 to 1998.
- Perry Karsen
-
Perry Karsen，自2020年10月起担任Graphite Bio, Inc.董事会主席，自2020年6月起担任Graphite Bio, Inc.董事会成员。从2013年5月到2015年12月，他担任Celgene Cellular Therapeutics, Inc. （Celgene Corporation的一个部门，统称为“Celgene”）的首席执行官。在此之前，他从2010年7月到2013年5月担任Celgene的首席运营官和执行副总裁，从2004年到2009年担任Celgene的高级副总裁和全球业务发展主管。从2009年2月到2010年7月，Karsen先生担任Pearl Therapeutics Inc.（随后被AstraZeneca plc收购）的首席执行官。（纳斯达克：下跌）。在此之前，Karsen先生曾担任Human Genome Sciences, Inc.（上市的生物技术公司，自被GlaxoSmithKline plc (Swiss： GSK.SW）收购）、Bristol-Myers Squibb Co.、Genentech, Inc.（自被Hoffmann-La Roche AG (Roche）收购）和Abbott Laboratories的高管职位。此外，他曾担任Pequot Capital Management, Inc.的普通合伙人。他目前是Jounce Therapeutics, Inc.（纳斯达克股票代码：JNCE）的董事会成员（2016年1月以来）和Nitrase Therapeutics, Inc.（2020年5月以来）的董事会成员。Karsen先生曾担任多家上市生物技术公司的董事会成员，包括2016年4月至2020年12月Intellia Therapeutics, Inc.（纳斯达克股票代码：INTL）， 2016年1月至2019年4月Oncomed Pharmaceuticals, Inc.（纳斯达克股票代码：OMED）（直到被Mereo BioPharma（纳斯达克股票代码：MREO）收购），2015年7月至2019年8月Voyager Therapeutics, Inc.（纳斯达克股票代码：VYGR）， Agios Pharmaceuticals, Inc.（纳斯达克股票代码：AGIO） 2011年11月至2016年3月和Alliqua Biomedical, Inc.（纳斯达克股票代码：MREO）。从2013年12月到2016年2月。他还曾担任the Biotechnology Innovation Organization （BIO）和the Alliance for Regenerative Medicine的董事会成员。他持有University of Illinois, Urbana-Champaign生物科学学士学位、Northwestern University's Kellogg Graduate School管理硕士学位和Duke University生物学硕士学位。
Perry Karsen,has served as the chair of Graphite Bio, Inc. board of directors since October 2020 and as a member of Graphite Bio, Inc. board of directors since June 2020. From May 2013 to December 2015, Mr. Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics, Inc., a division of Celgene Corporation (collectively, "Celgene"). Prior to that, Mr. Karsen served as Chief Operations Officer and Executive Vice President of Celgene from July 2010 to May 2013 and as Senior Vice President and Head of Worldwide Business Development of Celgene from 2004 to 2009. From February 2009 and July 2010, Mr. Karsen was Chief Executive Officer of Pearl Therapeutics Inc., subsequently acquired by AstraZeneca plc. (NASDAQ: AZN). Prior to that, Mr. Karsen held executive positions at Human Genome Sciences, Inc., a publicly traded biotechnology company (since acquired by GlaxoSmithKline plc (Swiss: GSK.SW)), Bristol-Myers Squibb Co., Genentech, Inc. (since acquired by Hoffmann-La Roche AG (Roche)), and Abbott Laboratories. In addition, Mr. Karsen served as a General Partner at Pequot Capital Management, Inc. He is currently a member of the boards of Jounce Therapeutics, Inc. (NASDAQ: JNCE) since January 2016 and Nitrase Therapeutics, Inc. since May 2020. Mr. Karsen formerly served on the boards of several public biotechnology companies, including Intellia Therapeutics, Inc. (NASDAQ: INTL) from April 2016 to December 2020, Oncomed Pharmaceuticals, Inc. (NASDAQ: OMED) (until it was acquired by Mereo BioPharma (NASDAQ: MREO)), from January 2016 to April 2019, Voyager Therapeutics, Inc. (NASDAQ: VYGR) from July 2015 to August 2019, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from November 2011 to March 2016, and Alliqua Biomedical, Inc. (NASDAQ: ALQA) from December 2013 to February 2016. Mr. Karsen was also formerly a member of the boards of directors of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine. Mr. Karsen received his B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign, a Masters of Management from Northwestern University's Kellogg Graduate School of Management and an M.A.T. in Biology from Duke University. - Perry Karsen，自2020年10月起担任Graphite Bio, Inc.董事会主席，自2020年6月起担任Graphite Bio, Inc.董事会成员。从2013年5月到2015年12月，他担任Celgene Cellular Therapeutics, Inc. （Celgene Corporation的一个部门，统称为“Celgene”）的首席执行官。在此之前，他从2010年7月到2013年5月担任Celgene的首席运营官和执行副总裁，从2004年到2009年担任Celgene的高级副总裁和全球业务发展主管。从2009年2月到2010年7月，Karsen先生担任Pearl Therapeutics Inc.（随后被AstraZeneca plc收购）的首席执行官。（纳斯达克：下跌）。在此之前，Karsen先生曾担任Human Genome Sciences, Inc.（上市的生物技术公司，自被GlaxoSmithKline plc (Swiss： GSK.SW）收购）、Bristol-Myers Squibb Co.、Genentech, Inc.（自被Hoffmann-La Roche AG (Roche）收购）和Abbott Laboratories的高管职位。此外，他曾担任Pequot Capital Management, Inc.的普通合伙人。他目前是Jounce Therapeutics, Inc.（纳斯达克股票代码：JNCE）的董事会成员（2016年1月以来）和Nitrase Therapeutics, Inc.（2020年5月以来）的董事会成员。Karsen先生曾担任多家上市生物技术公司的董事会成员，包括2016年4月至2020年12月Intellia Therapeutics, Inc.（纳斯达克股票代码：INTL）， 2016年1月至2019年4月Oncomed Pharmaceuticals, Inc.（纳斯达克股票代码：OMED）（直到被Mereo BioPharma（纳斯达克股票代码：MREO）收购），2015年7月至2019年8月Voyager Therapeutics, Inc.（纳斯达克股票代码：VYGR）， Agios Pharmaceuticals, Inc.（纳斯达克股票代码：AGIO） 2011年11月至2016年3月和Alliqua Biomedical, Inc.（纳斯达克股票代码：MREO）。从2013年12月到2016年2月。他还曾担任the Biotechnology Innovation Organization （BIO）和the Alliance for Regenerative Medicine的董事会成员。他持有University of Illinois, Urbana-Champaign生物科学学士学位、Northwestern University's Kellogg Graduate School管理硕士学位和Duke University生物学硕士学位。
- Perry Karsen,has served as the chair of Graphite Bio, Inc. board of directors since October 2020 and as a member of Graphite Bio, Inc. board of directors since June 2020. From May 2013 to December 2015, Mr. Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics, Inc., a division of Celgene Corporation (collectively, "Celgene"). Prior to that, Mr. Karsen served as Chief Operations Officer and Executive Vice President of Celgene from July 2010 to May 2013 and as Senior Vice President and Head of Worldwide Business Development of Celgene from 2004 to 2009. From February 2009 and July 2010, Mr. Karsen was Chief Executive Officer of Pearl Therapeutics Inc., subsequently acquired by AstraZeneca plc. (NASDAQ: AZN). Prior to that, Mr. Karsen held executive positions at Human Genome Sciences, Inc., a publicly traded biotechnology company (since acquired by GlaxoSmithKline plc (Swiss: GSK.SW)), Bristol-Myers Squibb Co., Genentech, Inc. (since acquired by Hoffmann-La Roche AG (Roche)), and Abbott Laboratories. In addition, Mr. Karsen served as a General Partner at Pequot Capital Management, Inc. He is currently a member of the boards of Jounce Therapeutics, Inc. (NASDAQ: JNCE) since January 2016 and Nitrase Therapeutics, Inc. since May 2020. Mr. Karsen formerly served on the boards of several public biotechnology companies, including Intellia Therapeutics, Inc. (NASDAQ: INTL) from April 2016 to December 2020, Oncomed Pharmaceuticals, Inc. (NASDAQ: OMED) (until it was acquired by Mereo BioPharma (NASDAQ: MREO)), from January 2016 to April 2019, Voyager Therapeutics, Inc. (NASDAQ: VYGR) from July 2015 to August 2019, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from November 2011 to March 2016, and Alliqua Biomedical, Inc. (NASDAQ: ALQA) from December 2013 to February 2016. Mr. Karsen was also formerly a member of the boards of directors of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine. Mr. Karsen received his B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign, a Masters of Management from Northwestern University's Kellogg Graduate School of Management and an M.A.T. in Biology from Duke University.
高管简历
中英对照 | 中文 | 英文- Josh Lehrer
Josh Lehrer自2020年4月起担任我们的总裁兼首席执行官兼董事会成员。从2013年10月到2020年4月，Lehrer博士在全球血液疗法公司担任过各种领导职务，包括首席医疗官。从2009年9月到2013年10月，Lehrer博士在Genentech担任临床开发和业务开发的领导职务。莱勒博士还曾在斯坦福大学医学中心和帕洛阿尔托医疗系统担任主治医师。他拥有哈佛大学生化科学学士学位和剑桥大学生物科学哲学硕士学位。Lehrer博士在加利福尼亚大学旧金山分校UCSF医学院获得了医学博士学位，并完成了在UCSF的内科住院医师资格。Lehrer博士曾在斯坦福大学担任心血管医学的临床和博士后研究员，并参加了斯坦福商学院的创业研究所。
Josh Lehrer,has served as Graphite Bio, Inc. President, Chief Executive Officer and on Graphite Bio, Inc. board of directors since April 2020. From October 2013 to April 2020, Dr. Lehrer held various leadership roles at Global Blood Therapeutics, Inc. (NASDAQ: GBT) (acquired by Pfizer, Inc. in October 2022), including Chief Medical Officer where he oversaw the development and approval of Oxbryta (voxelotor) for the treatment of sickle cell disease. From September 2009 to October 2013, Dr. Lehrer served in leadership roles at Genentech, Inc. in clinical development and business development. Dr. Lehrer has also held attending physician roles at Stanford University Medical Center and the Palo Alto Veteran's Affairs Health System. He holds an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. Dr. Lehrer earned his Doctor of Medicine at the University of California, San Francisco (UCSF), School of Medicine and completed his residency at UCSF in Internal Medicine. Dr. Lehrer served as a Clinical and Postdoctoral Fellow in cardiovascular medicine at Stanford University and attended the Institute for Entrepreneurship at the Stanford Graduate School of Business.- Josh Lehrer自2020年4月起担任我们的总裁兼首席执行官兼董事会成员。从2013年10月到2020年4月，Lehrer博士在全球血液疗法公司担任过各种领导职务，包括首席医疗官。从2009年9月到2013年10月，Lehrer博士在Genentech担任临床开发和业务开发的领导职务。莱勒博士还曾在斯坦福大学医学中心和帕洛阿尔托医疗系统担任主治医师。他拥有哈佛大学生化科学学士学位和剑桥大学生物科学哲学硕士学位。Lehrer博士在加利福尼亚大学旧金山分校UCSF医学院获得了医学博士学位，并完成了在UCSF的内科住院医师资格。Lehrer博士曾在斯坦福大学担任心血管医学的临床和博士后研究员，并参加了斯坦福商学院的创业研究所。
- Josh Lehrer,has served as Graphite Bio, Inc. President, Chief Executive Officer and on Graphite Bio, Inc. board of directors since April 2020. From October 2013 to April 2020, Dr. Lehrer held various leadership roles at Global Blood Therapeutics, Inc. (NASDAQ: GBT) (acquired by Pfizer, Inc. in October 2022), including Chief Medical Officer where he oversaw the development and approval of Oxbryta (voxelotor) for the treatment of sickle cell disease. From September 2009 to October 2013, Dr. Lehrer served in leadership roles at Genentech, Inc. in clinical development and business development. Dr. Lehrer has also held attending physician roles at Stanford University Medical Center and the Palo Alto Veteran's Affairs Health System. He holds an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. Dr. Lehrer earned his Doctor of Medicine at the University of California, San Francisco (UCSF), School of Medicine and completed his residency at UCSF in Internal Medicine. Dr. Lehrer served as a Clinical and Postdoctoral Fellow in cardiovascular medicine at Stanford University and attended the Institute for Entrepreneurship at the Stanford Graduate School of Business.
- Alethia Young
Alethia Young，自2022年4月起担任Graphite Bio, Inc.首席财务官。在加入本公司之前，Young女士曾在Cantor Fitzgerald，L.P.担任高级生物技术分析师和研究主管，管理股票研究部，涵盖大型资本和中小型资本生物技术公司。在2018年加入Cantor Fitzgerald，L.P.之前，Young女士曾在瑞士信贷和德意志银行担任高级生物技术分析师职位。在她职业生涯的早期，她是Marwood Group的研究政策分析师和总裁，为机构投资者提供以医疗保健为重点的咨询服务。她的职业生涯始于摩根大通投资银行和资产管理部门。自2022年6月起担任PTC Therapeutics，Inc.（纳斯达克股票代码：PTCT）和非营利组织BUILD NYC的董事会成员。杨女士在杜克大学获得了经济学和西班牙语学士学位。
Alethia Young,has served as Graphite Bio, Inc. Chief Financial Officer since April 2022. Prior to joining the Company, Ms. Young served as Senior Biotech Analyst and Head of Research at Cantor Fitzgerald, L.P., managing the Equity Research Department covering large capital and small-mid-capital biotechnology companies. Prior to joining Cantor Fitzgerald, L.P. in 2018, Ms. Young held Senior Biotech Analyst positions at Credit Suisse and Deutsche Bank AG. Earlier in her career, she was a Research Policy Analyst and President at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan Chase and Co. in the investment banking and asset management divisions. She currently serves on the board of directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) since June 2022 and BUILD NYC, a non-profit organization. Ms. Young earned a B.A. in Economics and Spanish from Duke University.- Alethia Young，自2022年4月起担任Graphite Bio, Inc.首席财务官。在加入本公司之前，Young女士曾在Cantor Fitzgerald，L.P.担任高级生物技术分析师和研究主管，管理股票研究部，涵盖大型资本和中小型资本生物技术公司。在2018年加入Cantor Fitzgerald，L.P.之前，Young女士曾在瑞士信贷和德意志银行担任高级生物技术分析师职位。在她职业生涯的早期，她是Marwood Group的研究政策分析师和总裁，为机构投资者提供以医疗保健为重点的咨询服务。她的职业生涯始于摩根大通投资银行和资产管理部门。自2022年6月起担任PTC Therapeutics，Inc.（纳斯达克股票代码：PTCT）和非营利组织BUILD NYC的董事会成员。杨女士在杜克大学获得了经济学和西班牙语学士学位。
- Alethia Young,has served as Graphite Bio, Inc. Chief Financial Officer since April 2022. Prior to joining the Company, Ms. Young served as Senior Biotech Analyst and Head of Research at Cantor Fitzgerald, L.P., managing the Equity Research Department covering large capital and small-mid-capital biotechnology companies. Prior to joining Cantor Fitzgerald, L.P. in 2018, Ms. Young held Senior Biotech Analyst positions at Credit Suisse and Deutsche Bank AG. Earlier in her career, she was a Research Policy Analyst and President at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan Chase and Co. in the investment banking and asset management divisions. She currently serves on the board of directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) since June 2022 and BUILD NYC, a non-profit organization. Ms. Young earned a B.A. in Economics and Spanish from Duke University.